IsomAb Ltd, a UK-based biotechnology company, has appointed Dr. Philip Brainin as Chief Executive Officer (CEO) and member of the Board of Directors.

Brainin is tasked with taking lead candidate ISM-001 for chronic stable angina (CSA) into clinical development. ISM-001’s preclinical data showing complete restoration of blood flow in severe ischemic disease models supports the company’s stated goal of delivering a disease-modifying treatment for chronic stable angina (CSA), a condition affecting 9 million patients in the U.S. alone.

Experience

Brainin is physician-scientist with extensive training in clinical cardiology, and brings a combination of cardiovascular medicine, clinical research, and venture investing experience across EU and U.S. biotechnology companies. He has invested in multiple early-stage therapeutics companies, advised Boards of Directors including for AnaCardio and NephroDI, and has shaped corporate and business development strategies for portfolio companies to enable financing, partnerships, and exits.

“With my background in cardiology, I see every day how limited our options are for patients with ischaemic disease,” said Brainin. “What excites me about IsomAb is that ISM-001 is not just another VEGF therapy. The pioneering mechanistic and pharmacological data generated by the team shows that IsomAb’s unique approach targeting VEGF-A165b removes the brakes on angiogenesis that are applied in ischemic disease, allowing blood vessels to grow, remodel and create durable new arteries. Once proof of concept is demonstrated in the clinic, I envisage a clear pathway for regulatory, manufacturing and commercial success.”